[
  {
    "ts": null,
    "headline": "FDA reversal on mRNA-1010 could transform the seasonal influenza vaccines market",
    "summary": "In addition to advancing the seasonal influenza vaccines market, the potential FDA approval of mRNA-1010 will also stake Moderna’s claim in the market.",
    "url": "https://finnhub.io/api/news?id=4360befc5532d9467188c25da74e0ccfee2fe5ba5a09dc8eac16c051da7d61fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772035712,
      "headline": "FDA reversal on mRNA-1010 could transform the seasonal influenza vaccines market",
      "id": 139216108,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "In addition to advancing the seasonal influenza vaccines market, the potential FDA approval of mRNA-1010 will also stake Moderna’s claim in the market.",
      "url": "https://finnhub.io/api/news?id=4360befc5532d9467188c25da74e0ccfee2fe5ba5a09dc8eac16c051da7d61fb"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Avoid MRNA and 1 Stock to Buy Instead",
    "summary": "What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 99.8%, hitting $50.65. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
    "url": "https://finnhub.io/api/news?id=5daa0baa0710da754a10dbf396c9023939e95900ba34f110365f3b2a8b43bf75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772029295,
      "headline": "3 Reasons to Avoid MRNA and 1 Stock to Buy Instead",
      "id": 139210899,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 99.8%, hitting $50.65. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
      "url": "https://finnhub.io/api/news?id=5daa0baa0710da754a10dbf396c9023939e95900ba34f110365f3b2a8b43bf75"
    }
  },
  {
    "ts": null,
    "headline": "Moderna's Ups and Downs: Here's What You Need to Know Before Investing.",
    "summary": "The stock, after a few tough years, soared in the double-digits in January.",
    "url": "https://finnhub.io/api/news?id=582d01d0604e195b98dd8b6fb5f51401bd079b2ac16c4c7ad52708f7d326a512",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772026500,
      "headline": "Moderna's Ups and Downs: Here's What You Need to Know Before Investing.",
      "id": 139207438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The stock, after a few tough years, soared in the double-digits in January.",
      "url": "https://finnhub.io/api/news?id=582d01d0604e195b98dd8b6fb5f51401bd079b2ac16c4c7ad52708f7d326a512"
    }
  },
  {
    "ts": null,
    "headline": "A Fresh Look At Moderna (MRNA) Valuation After A Sharp Share Price Rebound",
    "summary": "Why Moderna Stock Is Back on Investors’ Radar Moderna (MRNA) has reappeared on many watchlists after a mixed set of signals, including a recent share price near $50.52, positive revenue growth, a sizeable net income loss, and strong recent return figures. See our latest analysis for Moderna. At a share price of $50.52, Moderna has seen sharp recent momentum, with a 15.0% 7 day share price return and 102.0% 90 day share price return. However, the 5 year total shareholder return of a 65.59%...",
    "url": "https://finnhub.io/api/news?id=597f01334d7ec1e7eb8a9a0121c343f0142e77838f03736588e339c09bb5c81c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772007197,
      "headline": "A Fresh Look At Moderna (MRNA) Valuation After A Sharp Share Price Rebound",
      "id": 139206005,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Why Moderna Stock Is Back on Investors’ Radar Moderna (MRNA) has reappeared on many watchlists after a mixed set of signals, including a recent share price near $50.52, positive revenue growth, a sizeable net income loss, and strong recent return figures. See our latest analysis for Moderna. At a share price of $50.52, Moderna has seen sharp recent momentum, with a 15.0% 7 day share price return and 102.0% 90 day share price return. However, the 5 year total shareholder return of a 65.59%...",
      "url": "https://finnhub.io/api/news?id=597f01334d7ec1e7eb8a9a0121c343f0142e77838f03736588e339c09bb5c81c"
    }
  }
]